Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Measuring uptake and effectiveness of direct-acting antiviral treatment for hepatitis C among key populations in Ontario: a population-based retrospective cohort study
EF 2020-21
Résumé
Hepatitis C virus (HepC) targets the liver and, if left untreated, can lead to cirrhosis, liver cancer, and death. HepC is a major public health problem in Canada, affecting an estimated 250,000 Canadians and leading to more years of life lost than any other infectious disease. However, with the advent of a HepC cure (direct-acting antiviral treatment) in 2015, public health efforts have shifted towards the elimination of HepC. Achieving elimination will require reaching key populations - including people who inject drugs and immigrants from HepC-endemic countries - that are disproportionately burdened by HepC and who may also experience unique challenges in accessing healthcare. To date, there is a lack of research assessing the uptake and effectiveness of direct-acting antiviral treatment for HepC in Ontario at a population-level, both overall and within key populations - my proposed research project aims to fill this knowledge gap.
This proposed research will use data from a population-based cohort of people living with chronic HepC in Ontario to address the following objectives: 1) measure direct-acting antiviral treatment uptake in Ontario; 2) identify potential disparities in direct-acting antiviral treatment uptake among key populations; 3) estimate the effect of direct-acting antiviral treatment on health outcomes including liver-related and all-cause mortality and explore whether treatment effectiveness differs meaningfully between members of key populations and other Ontarians.
This research will provide evidence on the uptake and effectiveness direct-acting antiviral treatment among all Ontarians with chronic HepC. Planned comparisons of treatment uptake and effectiveness between members of key populations and other Ontarians may inform future provincial (or national) interventions to reduce HepC-related disparities and work towards HepC elimination.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
439390
Name
Greenwald Zoë
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Measuring uptake and effectiveness of direct-acting antiviral treatment for hepatitis C among key populations in Ontario: a population-based retrospective cohort study
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Direct-Acting Antivirals; Health Administrative Data; Health Disparities Research; Hepatitis C Virus; Immigrant Populations; People Who Inject Drugs; Population-Based Cohorts
Abstract
Hepatitis C virus (HepC) targets the liver and, if left untreated, can lead to cirrhosis, liver cancer, and death. HepC is a major public health problem in Canada, affecting an estimated 250,000 Canadians and leading to more years of life lost than any other infectious disease. However, with the advent of a HepC cure (direct-acting antiviral treatment) in 2015, public health efforts have shifted towards the elimination of HepC. Achieving elimination will require reaching key populations - including people who inject drugs and immigrants from HepC-endemic countries - that are disproportionately burdened by HepC and who may also experience unique challenges in accessing healthcare. To date, there is a lack of research assessing the uptake and effectiveness of direct-acting antiviral treatment for HepC in Ontario at a population-level, both overall and within key populations - my proposed research project aims to fill this knowledge gap.
This proposed research will use data from a population-based cohort of people living with chronic HepC in Ontario to address the following objectives: 1) measure direct-acting antiviral treatment uptake in Ontario; 2) identify potential disparities in direct-acting antiviral treatment uptake among key populations; 3) estimate the effect of direct-acting antiviral treatment on health outcomes including liver-related and all-cause mortality and explore whether treatment effectiveness differs meaningfully between members of key populations and other Ontarians.
This research will provide evidence on the uptake and effectiveness direct-acting antiviral treatment among all Ontarians with chronic HepC. Planned comparisons of treatment uptake and effectiveness between members of key populations and other Ontarians may inform future provincial (or national) interventions to reduce HepC-related disparities and work towards HepC elimination.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Greenwald, Zoë
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~